PMC:7417114 / 34547-34888 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T189","span":{"begin":317,"end":323},"obj":"Body_part"}],"attributes":[{"id":"A189","pred":"fma_id","subj":"T189","obj":"http://purl.org/sig/ont/fma/fma9601"}],"text":"The CDK4/6 inhibitor, abemaciclib, was identified as one of 24 FDA-approved drugs to display in vitro activity against SARS-CoV-2 (0.1 μM\u003cIC50\u003c10 μM); these results are unpublished and are reported as a preprint (BioRxiv. 10.1101/2020.03.20.999730) (Table 1). Abemaciclib has been approved for advanced or metastatic breast cancer (Table 2)."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T44","span":{"begin":317,"end":323},"obj":"Body_part"}],"attributes":[{"id":"A44","pred":"uberon_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/UBERON_0000310"}],"text":"The CDK4/6 inhibitor, abemaciclib, was identified as one of 24 FDA-approved drugs to display in vitro activity against SARS-CoV-2 (0.1 μM\u003cIC50\u003c10 μM); these results are unpublished and are reported as a preprint (BioRxiv. 10.1101/2020.03.20.999730) (Table 1). Abemaciclib has been approved for advanced or metastatic breast cancer (Table 2)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T381","span":{"begin":119,"end":127},"obj":"Disease"},{"id":"T382","span":{"begin":317,"end":330},"obj":"Disease"},{"id":"T383","span":{"begin":324,"end":330},"obj":"Disease"}],"attributes":[{"id":"A381","pred":"mondo_id","subj":"T381","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A382","pred":"mondo_id","subj":"T382","obj":"http://purl.obolibrary.org/obo/MONDO_0007254"},{"id":"A383","pred":"mondo_id","subj":"T383","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"}],"text":"The CDK4/6 inhibitor, abemaciclib, was identified as one of 24 FDA-approved drugs to display in vitro activity against SARS-CoV-2 (0.1 μM\u003cIC50\u003c10 μM); these results are unpublished and are reported as a preprint (BioRxiv. 10.1101/2020.03.20.999730) (Table 1). Abemaciclib has been approved for advanced or metastatic breast cancer (Table 2)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T434","span":{"begin":102,"end":110},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T435","span":{"begin":201,"end":202},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T436","span":{"begin":272,"end":275},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T437","span":{"begin":317,"end":323},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"}],"text":"The CDK4/6 inhibitor, abemaciclib, was identified as one of 24 FDA-approved drugs to display in vitro activity against SARS-CoV-2 (0.1 μM\u003cIC50\u003c10 μM); these results are unpublished and are reported as a preprint (BioRxiv. 10.1101/2020.03.20.999730) (Table 1). Abemaciclib has been approved for advanced or metastatic breast cancer (Table 2)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T305","span":{"begin":11,"end":20},"obj":"Chemical"},{"id":"T306","span":{"begin":76,"end":81},"obj":"Chemical"}],"attributes":[{"id":"A305","pred":"chebi_id","subj":"T305","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A306","pred":"chebi_id","subj":"T306","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"The CDK4/6 inhibitor, abemaciclib, was identified as one of 24 FDA-approved drugs to display in vitro activity against SARS-CoV-2 (0.1 μM\u003cIC50\u003c10 μM); these results are unpublished and are reported as a preprint (BioRxiv. 10.1101/2020.03.20.999730) (Table 1). Abemaciclib has been approved for advanced or metastatic breast cancer (Table 2)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1197","span":{"begin":4,"end":10},"obj":"Gene"},{"id":"1198","span":{"begin":119,"end":129},"obj":"Species"},{"id":"1199","span":{"begin":317,"end":330},"obj":"Disease"}],"attributes":[{"id":"A1197","pred":"tao:has_database_id","subj":"1197","obj":"Gene:1019"},{"id":"A1198","pred":"tao:has_database_id","subj":"1198","obj":"Tax:2697049"},{"id":"A1199","pred":"tao:has_database_id","subj":"1199","obj":"MESH:D001943"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The CDK4/6 inhibitor, abemaciclib, was identified as one of 24 FDA-approved drugs to display in vitro activity against SARS-CoV-2 (0.1 μM\u003cIC50\u003c10 μM); these results are unpublished and are reported as a preprint (BioRxiv. 10.1101/2020.03.20.999730) (Table 1). Abemaciclib has been approved for advanced or metastatic breast cancer (Table 2)."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T88","span":{"begin":317,"end":330},"obj":"Phenotype"}],"attributes":[{"id":"A88","pred":"hp_id","subj":"T88","obj":"http://purl.obolibrary.org/obo/HP_0003002"}],"text":"The CDK4/6 inhibitor, abemaciclib, was identified as one of 24 FDA-approved drugs to display in vitro activity against SARS-CoV-2 (0.1 μM\u003cIC50\u003c10 μM); these results are unpublished and are reported as a preprint (BioRxiv. 10.1101/2020.03.20.999730) (Table 1). Abemaciclib has been approved for advanced or metastatic breast cancer (Table 2)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T271","span":{"begin":0,"end":221},"obj":"Sentence"},{"id":"T272","span":{"begin":222,"end":259},"obj":"Sentence"},{"id":"T273","span":{"begin":260,"end":341},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The CDK4/6 inhibitor, abemaciclib, was identified as one of 24 FDA-approved drugs to display in vitro activity against SARS-CoV-2 (0.1 μM\u003cIC50\u003c10 μM); these results are unpublished and are reported as a preprint (BioRxiv. 10.1101/2020.03.20.999730) (Table 1). Abemaciclib has been approved for advanced or metastatic breast cancer (Table 2)."}